Literature DB >> 9200345

The natural history of deep-vein thrombosis.

P Prandoni1, A W Lensing, M R Prins.   

Abstract

Symptomatic deep vein thrombosis (DVT) carries a high risk for recurrent venous thromboembolism that persists for many years. This risk is dependent on readily identifiable risk factors, being low after a trauma or a surgical intervention, and higher in all the other patient categories. Severe post-thrombotic manifestations seem related with ipsilateral recurrence of DVT but are rare in patients with a first episode of venous thrombosis adequately treated with anticoagulant drugs and wearing compression elastic stockings. In the absence of malignancy, the prognosis with regard to survival is good.

Entities:  

Mesh:

Year:  1997        PMID: 9200345     DOI: 10.1055/s-2007-996089

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  4 in total

1.  Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.

Authors:  P T T Kinnunen; T J Murtola; K Talala; K Taari; T L J Tammela; A Auvinen
Journal:  Cancer Causes Control       Date:  2019-06-17       Impact factor: 2.506

Review 2.  Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.

Authors:  Sean D Sullivan; Susan R Kahn; Bruce L Davidson; Lars Borris; Patrick Bossuyt; Gary Raskob
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 3.  Thrombosis Complications in Pediatric Acute Lymphoblastic Leukemia: Risk Factors, Management, and Prevention: Is There Any Role for Pharmacologic Prophylaxis?

Authors:  Vilmarie Rodriguez
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

4.  Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.

Authors:  Pete T T Kinnunen; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.